How Long Before Wegovy Starts Working: Your Timeline to Sustainable Weight Loss

Last reviewed: June 19, 2026

Last updated: June 19, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Wegovy begins acting pharmacologically after the first dose, but the timeline that matters is measured in months, not days. The Wegovy prescribing information specifies a starting dosage of 0.25 mg once weekly for four weeks followed by escalation every four weeks toward a maintenance dosage, and every registration trial that established its efficacy measured the primary endpoint at week 64, 68, or 72. Semaglutide has an elimination half-life of approximately one week, which means concentrations from a given dose level take roughly four to five weeks to plateau. Anything you read that promises a specific result by a specific week is describing an expectation, not a labeled finding.

The Pharmacokinetics Set the Floor

Absolute bioavailability of semaglutide following subcutaneous administration is 89 percent, and maximum concentration after a dose is reached one to three days later. The elimination half-life is approximately one week. A drug with a one-week half-life reaches steady state after roughly four to five half-lives — which is why each labeled escalation step is four weeks long rather than arbitrary.

That same property works in the other direction. The label notes that with an elimination half-life of approximately one week, semaglutide will be present in the circulation for about five to seven weeks after the last dose. The molecule is slow in both directions, and the timeline reflects that.

What the Labeled Escalation Schedule Implies About Timing

Wegovy injection is initiated at 0.25 mg once weekly for four weeks, then escalated every four weeks according to the schedule in the labeling until the maintenance dosage is reached. The usual recommended maintenance dosage of Wegovy injection is 2.4 mg once weekly.

The arithmetic of that schedule means someone following it is spending the first several months below the maintenance dose. The doses in that window are not placebo — appetite effects commonly appear earlier — but the efficacy figures quoted in the label were generated in people who reached and sustained maintenance dosing for the better part of a year. The specific schedule for any individual belongs to their prescriber.

What the Trials Measured, and When

Study 2 in the Wegovy label — the trial published as STEP 1 — was a 68-week trial that enrolled 1,961 patients with obesity, or with overweight plus at least one weight-related comorbid condition, excluding type 2 diabetes. At week 68, mean change in body weight was −14.9 percent with Wegovy 2.4 mg versus −2.4 percent with placebo. The published report appeared as Once-Weekly Semaglutide in Adults with Overweight or Obesity in the New England Journal of Medicine in 2021.

Study 8, a 72-week trial in 1,407 patients with obesity, compared Wegovy 7.2 mg with Wegovy 2.4 mg and placebo, reporting mean weight changes of −18.8 percent, −15.5 percent, and −3.9 percent respectively. Study 3, in 807 patients with type 2 diabetes, reported −9.6 percent versus −3.4 percent at week 68 — a reminder that the same drug produces different average results in different populations.

Every one of those numbers is an endpoint measured at the end of more than a year of treatment. None of them is a four-week or six-week figure, because none of those trials had a four-week or six-week primary endpoint.

Why Early Weeks Feel Different Than They Look

Appetite and satiety changes are frequently noticed early, and there is a mechanistic reason: GLP-1 receptor agonism slows gastric emptying and acts on central appetite regulation from the first exposure. What is different is the scale of the effect at 0.25 mg compared with a maintenance dose.

Weight itself is also a noisy signal week to week. Fluid shifts, glycogen stores, sodium intake, and measurement conditions can each move the scale by more than a week of genuine fat loss. This is why trial endpoints are computed as least-squares means across large groups over long periods rather than from individual weekly readings.

The Trials Included More Than the Drug

In Studies 2, 3, 5, 7, 8, and 9, all patients received instruction for a reduced-calorie diet of approximately a 500 kcal per day deficit and physical activity counseling recommending a minimum of 150 minutes per week, beginning with the first dose and continuing throughout the trial. In Study 4, patients received an initial eight-week low-calorie diet followed by 60 weeks of a reduced-calorie diet and increased physical activity building from 100 to 200 minutes per week.

The label indication itself reads "in combination with a reduced calorie diet and increased physical activity." The published results are results of a combined intervention. Reading them as the effect of an injection alone overstates what was tested.

What Discontinuation Reveals About the Timeline

Study 5 in the label was a randomized withdrawal trial: after a 20-week run-in on Wegovy, patients who reached 2.4 mg were randomized either to continue or to switch to placebo. From week 20 to week 68, those who continued lost a further 7.9 percent of body weight, while those switched to placebo regained 6.9 percent — a difference of 14.8 percent.

That result reframes the question. The relevant timeline is not how long until something happens; it is that the effect is contingent on continued treatment. The label describes the indication as reducing excess body weight and maintaining weight reduction long term, and the maintenance half of that phrase is doing real work.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

How long does Wegovy take to start working?

Pharmacologically it begins after the first dose — maximum concentration is reached one to three days later — but meaningful weight change accrues over months. The labeled schedule starts at 0.25 mg once weekly for four weeks with escalation every four weeks toward a maintenance dosage, and the registration trials measured their primary endpoints at week 64, 68, or 72 rather than in the first weeks.

How much weight did people lose in the Wegovy trials?

In Study 2 of the label, a 68-week trial in 1,961 patients, mean change in body weight was −14.9 percent with Wegovy 2.4 mg versus −2.4 percent with placebo. In Study 8, a 72-week trial in 1,407 patients, the figures were −18.8 percent at 7.2 mg, −15.5 percent at 2.4 mg, and −3.9 percent with placebo. In Study 3, in patients with type 2 diabetes, −9.6 percent versus −3.4 percent.

Why does Wegovy start at a low dose?

The labeled escalation exists to reduce gastrointestinal adverse reactions, which are the most common adverse effects of GLP-1 receptor agonists. Because semaglutide has an elimination half-life of approximately one week, concentrations at any given dose level take roughly four to five weeks to plateau, which is why each labeled step is four weeks long. Your specific schedule is set by your prescriber.

Is it normal not to see weight loss in the first month?

Body weight is a noisy week-to-week signal — fluid shifts, glycogen, sodium intake, and measurement conditions all move it. The trial results cited in the Wegovy label are least-squares means across large groups measured after more than a year, not short-term readings. If you have concerns about your response, the productive step is reviewing it with the clinician managing your treatment.

What happens if Wegovy is stopped?

The label reports a randomized withdrawal trial in which patients who reached 2.4 mg after a 20-week run-in were randomized to continue or switch to placebo. From week 20 to week 68, those continuing lost a further 7.9 percent of body weight while those on placebo regained 6.9 percent. The labeled indication describes both reducing excess body weight and maintaining that reduction long term.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.